Background: To date, no data on the adherence to specific guidelines for children with chronic myeloid leukemia (CML) in chronic phase (CP) have been reported. Methods: Since 2001, guidelines for treatment with imatinib mesylate (IM) and monitoring in patients younger than 18 years with CP-CML have been shared with 9 pediatric referral centers (P centers) and 4 reference centers for adults and children/adolescents (AP centers) in Italy. In this study, the adherence to these guidelines was analyzed. Results: Thirty-four patients with a median age of 11.4 years and 23 patients with a median age of 11.0 years were managed at 9 P and at 4 AP centers, respectively. Evaluations of bone marrow (BM) and/or peripheral blood (PB) were available for more than 90% of evaluable patients. Cytogenetics and molecular monitoring of PB were more consistently performed in AP centers, whereas molecular analysis of BM was carried out more frequently in P centers. Before 2009, some patients who responded to IM underwent a transplantation, contrary to the guidelines' recommendations. Conclusions: Our experience shows that having specific guidelines is an important tool for an optimal management of childhood CP-CML, together with exchange of knowledge and proactive discussions within the network.

Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience / Giona, F; Santopietro, M; Menna, G; Putti, Mc; Micalizzi, C; Santoro, N; Ziino, O; Mura, R; Ladogana, S; Iaria, G; Sau, A; Burnelli, R; Vacca, N; Bernasconi, S; Consarino, C; Petruzziello, F; Moleti, Ml; Biondi, A; Locatelli, F; Foà, R.. - In: ACTA HAEMATOLOGICA. - ISSN 0001-5792. - 140:2(2018), pp. 105-111. [10.1159/000491546]

Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience

Giona F;Santopietro M;Menna G;Mura R;Bernasconi S;Moleti ML;Locatelli F;Foà R.
2018

Abstract

Background: To date, no data on the adherence to specific guidelines for children with chronic myeloid leukemia (CML) in chronic phase (CP) have been reported. Methods: Since 2001, guidelines for treatment with imatinib mesylate (IM) and monitoring in patients younger than 18 years with CP-CML have been shared with 9 pediatric referral centers (P centers) and 4 reference centers for adults and children/adolescents (AP centers) in Italy. In this study, the adherence to these guidelines was analyzed. Results: Thirty-four patients with a median age of 11.4 years and 23 patients with a median age of 11.0 years were managed at 9 P and at 4 AP centers, respectively. Evaluations of bone marrow (BM) and/or peripheral blood (PB) were available for more than 90% of evaluable patients. Cytogenetics and molecular monitoring of PB were more consistently performed in AP centers, whereas molecular analysis of BM was carried out more frequently in P centers. Before 2009, some patients who responded to IM underwent a transplantation, contrary to the guidelines' recommendations. Conclusions: Our experience shows that having specific guidelines is an important tool for an optimal management of childhood CP-CML, together with exchange of knowledge and proactive discussions within the network.
2018
Childhood leukemia; Chronic myeloid leukemia; Imatinib; Tyrosine kinases; Hematology
01 Pubblicazione su rivista::01a Articolo in rivista
Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience / Giona, F; Santopietro, M; Menna, G; Putti, Mc; Micalizzi, C; Santoro, N; Ziino, O; Mura, R; Ladogana, S; Iaria, G; Sau, A; Burnelli, R; Vacca, N; Bernasconi, S; Consarino, C; Petruzziello, F; Moleti, Ml; Biondi, A; Locatelli, F; Foà, R.. - In: ACTA HAEMATOLOGICA. - ISSN 0001-5792. - 140:2(2018), pp. 105-111. [10.1159/000491546]
File allegati a questo prodotto
File Dimensione Formato  
Giona_Real-Life Management_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 268.34 kB
Formato Adobe PDF
268.34 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1177283
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact